Lorber R R, Linzmayer M I
Clin Ther. 1985;7(3):338-46.
The effectiveness of netilmicin was evaluated retrospectively in 40 patients with culture-documented bacteremia due to Pseudomonas aeruginosa. Netilmicin was the only antibiotic active in vitro against P aeruginosa that was administered to these patients. In 18 patients, Pseudomonas bacteremia developed in association with a Pseudomonas infection of the urinary tract; in 22 patients, Pseudomonas bacteremia developed from nonurinary or unknown sources. A clinical resolution or improvement was observed in 92% of the evaluable patients, and P aeruginosa was eliminated from the blood of 90% of the patients. The drug had nephrotoxic effects in two patients, but in no patient was there subjective or audiometric evidence of ototoxic effects. Three patients died during therapy. Based on these data, netilmicin is effective, and is associated with a low incidence of toxic effects, in the treatment of patients with Pseudomonas bacteremia.
对40例经培养证实为铜绿假单胞菌菌血症的患者进行了奈替米星疗效的回顾性评估。奈替米星是唯一一种对这些患者体外有活性的抗铜绿假单胞菌抗生素。18例患者的铜绿假单胞菌菌血症与尿路感染相关；22例患者的铜绿假单胞菌菌血症源于非泌尿道或不明来源。在92%的可评估患者中观察到临床缓解或改善，90%的患者血液中的铜绿假单胞菌被清除。该药物在两名患者中产生了肾毒性作用，但没有患者有主观或听力测定证据表明存在耳毒性作用。三名患者在治疗期间死亡。基于这些数据，奈替米星在治疗铜绿假单胞菌菌血症患者方面是有效的，且毒性作用发生率较低。
